bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 3558: A pilot clinical study of limonene in women with early stage breast cancer: Effects of short-term treatment on tissue limonene disposition and serum markers
Authors: Miller Jessica A. , Lang Julie E. , Hsu Chiu-Hsieh , Ley Michele , Waer Amy L. , Cordova Catherine , Chow H-H. Sherry 
Published: August 2012

Abstract
Background: Limonene is a highly lipophilic monoterpene found in citrus peel oil that has demonstrated anticancer properties in preclinical studies. The purpose of this study was to evaluate whether limonene and its primary metabolite perillic acid (PA) would distribute extensively to the breast tissue and reach an effective drug concentration. Secondary endpoints included evaluation of changes in cancer-related biomarkers in plasma and tissue. Methods: Participants (N = 40) with newly diagnosed stage 0 - 2 breast cancer took 2 grams daily of oral limonene for 2 - 6 weeks (21.5 ± 8.8 days) prior to planned surgical tumor resection. Blood was drawn pre/post intervention for measurement of serum concentration of limonene, PA, and protein biomarkers, as well as to assess toxicity profiles. A small piece of breast tissue adjacent to the tumor mass was also collected for analysis of limonene and PA levels. Limonene and PA levels in tissue and serum were analyzed using specific chromatography-based assays. Results: Limonene was found to preferentially concentrate in breast tissue (332.3 + 336.1 uM) versus plasma (0.49 + 0.67 uM) with tissue-to-plasma concentration ratio (TPCR) of 1,667 + 312.5 (P&lt;0.001). PA did not concentrate in breast tissue (5.73 + 10.28 uM) versus plasma (3.89 + 6.81 uM) with TPCR of 1.4 + 0.56. Post-intervention serum levels of leptin, adiponectin, TGF-beta1, IGFBP-3 and IL-6 were unchanged from baseline. There was a small but statistically significant post-intervention increase in IGF-1, however the change was no longer significant after adjustment for number of days on agent. Possibly or probably related adverse events were primarily GI-related and were not dose-limiting. No clinically significant changes in complete blood count, renal, hepatic or other blood chemistry studies were noted. Analysis of the intervention effects on tissue biomarkers of proliferation, apoptosis, and cell cycle regulation is ongoing. Discussion: Oral limonene preferentially concentrates in the breast tissue and has a favorable side effect profile. PA does not readily concentrate in breast tissue when administered as oral limonene. Short-term limonene intervention resulted in minimal changes in systemic biomarkers. Further clinical trials with a longer intervention are necessary to establish limonene's potential role as a chemopreventive agent in breast cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3558. doi:1538-7445.AM2012-3558
Abstract 356: Photoacoustic imaging of pancreatic cancer proliferation via sigma-2 receptor/PGRMC1-eYFP
Authors: Xu Jinbin , Cai Xin , Yao Junjie , Dirk Spitzer , Zeng Chengbo , Hawkins William G. , Wang Lihong V. , Mach Robert H. 
Published: August 2012

Abstract
Sigma-2 receptor binding sites, recently identified as progesterone receptor membrane component 1 (PGRMC1) (Nature Communications, 2011; 2:380), are highly expressed in tumor cells. We have previously reported that measuring the sigma-2 receptor expression is a novel strategy for evaluating the proliferative status of tumors in vivo using the non-invasive imaging technique, positron emission tomography (PET). Our group has developed a series of sigma-2 receptor radioligands as PET imaging probes, one sigma-2 receptor radiotracer [18F]ISO-1 is under clinical evaluation for imaging the proliferation status in the patients with different types of cancers. PGRMC1 depleted human ovarian SKOV-3 cancer cells have been reported to lack tumor formation in mice and PGRMC1 depleted tumors displayed poor microvasculature system (Endocrinology, 2009; 150:4846-4854). To further understand the regulation of PGRMC1 in cell cycle and cancer proliferation, we have stably transfected PGRMC1-eYFP, enhanced yellow fluorescent protein conjugated PGRMC1, into human pancreatic BxPC3 cancer cells and those cells were transplanted into immunodeficient nude mice to grow into solid tumors; subsequently, a traditional fluorescence imaging system and an optical-resolution photoacoustic microscopy (OR-PAM) were utilized for in vivo monitoring of BxPC3 cancer cells growth and observing the surrounding microvasculature development for those tumors under conditions of sigma-2 receptor/PGRMC1 overexpression. Tumor tissue sections were prepared and in vitro fluorescence microscopy analysis of PGRMC1-eYFP cells revealed that PGRMC1-eYFP overexpressed cells form cluster patterns which may represent the proliferation priority created by PGRMC1 overexpression. The subcellular localization of PGRMC1-eYFP appeared to be similar to that of sigma-2 receptors reported previously by our group using the sigma-2 receptor fluorescent probes (Cancer Res 2007; 67, 6708-6716). PGRMC1-eYFP BxPC3 cells were surrounded by fully developed microvasculature system. Further application of this in vivo imaging platform for evaluating the sigma-2 receptor pharmacology and imaging proliferation is ongoing in our group. (Supported by CA 102869 and CA136398).
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 356. doi:1538-7445.AM2012-356
Abstract 3560: Application of metabolomics to assess serum profiles in limonene-treated breast cancer patients
Authors: Miller Jessica A. , Want Elizabeth J. , Thompson Patricia A. , Lang Julie E. , Lance Peter , Chow H-H. Sherry 
Published: August 2012

Abstract
Background. Limonene is a highly lipophilic monoterpene found in citrus peel that has demonstrated anticancer effects in preclinical models. Limonene likely affects multiple targets with varying potency. Advanced techniques to obtain metabolomic profiles from biofluids have the potential to provide a non-invasive means to assess these multiple effects. This strategy was applied to a clinical trial with women with early stage breast cancer receiving limonene treatment. Methods. Forty women with stage 0 - 2 breast cancer received 2 g QD limonene daily for 2 - 6 weeks (21.5 + 8.8 days) before scheduled surgical resection of their tumor. Pre/post intervention blood draws were taken for metabolomics analysis. Metabolomics profiling was conducted using ultra performance liquid chromatography tandem time-of-flight mass spectrometry (UPLC-QToF). Chromatographic separation was achieved using a gradient of two mobile phases; A: 0.1% formic acid in water, and B: 0.1% formic acid in methanol with a flow rate of 0.4 mL/min. A Waters Aquity UltraPerformance LC HSS T3 column was used. Metabolomics data was preprocessed with XCMS. Preliminary metabolite identification was conducted by mining the Human Metabolome Database (HMDB). Results. Over 1,000 metabolite features were identified by metabolomic profiling. In negative ion mode, three metabolites exhibited a 48-fold change or higher from pre to post-intervention; 183.1 m/z at 9.4 min, 177.0 m/z at 10.0 min, and 345.1 m/z 8.9 min (P's&lt;0.001). Two distinct peaks with m/z of 103.0 elute at 1.9 and 2.25 minutes respectively and changed &gt;20% (P's&lt;0.05). Twenty potential metabolites were identified in positive ion mode with &gt;20% change by the intervention (P's&lt; 0.05), of these, two exhibited 10-fold change or higher; 312.2 m/z at 8.7 min, and 369.2 m/z at 9.0 min (P's&lt;0.001). Discussion. This study demonstrates that 2 g QD daily oral limonene results in significant changes in approximately 20 metabolites in serum. Candidate compounds include limonene metabolites, carnitines and end products of arachindonic acid metabolism. Efforts are ongoing to identify these metabolites for analyte specific verification and quantitation. Further clinical trials with limonene are necessary to establish its potential role as a chemopreventive agent in breast cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3560. doi:1538-7445.AM2012-3560
Abstract 3565: Colorectal cancer screening among US adults with and without doctor's specific recommendation regarding choice of screening modality
Authors: Laiyemo Adeyinka O. , Doubeni Chyke , Adebogun Akeem O. , McDonald-Pinkett Shelly , Han Paul , Meissner Helen I. , Klabunde Carrie 
Published: August 2012

Abstract
Background: Absence of a physician's recommendation is among the most commonly reported barriers to undergoing colorectal cancer (CRC) screening. It is unknown whether a physician's specific recommendation of a particular screening modality, rather than a patient's choice from a menu of screening options, improves CRC screening uptake. Aim: To assess whether healthcare providers’ discussion of CRC screening options and recommending a specific screening modality improve uptake of screening. Methods: We used the 2007 Health Information National Trends Survey (HINTS) to evaluate how respondents who were 50 years and older (n = 4,342) were informed of CRC screening. We used logistic regression analyses to examine the association of recommendations and being current with CRC screening (Fecal occult blood testing (FOBT) within 1 year, sigmoidoscopy within 5 years, or colonoscopy within 10 years). Results: The mean age of responders was 64.9 years, 60.3% female, 81.5% white, 8.6% black, and 92.7% had health insurance. CRC screening discussions occurred with 3,320 (77.5%) respondents; 94.7% of which occurred with a doctor as opposed to a nurse or other health care professional. Colonoscopy was the most recommended test. Overall, 2,824 (65.0%) respondents were up to date with CRC screening regardless of the screening modality. After adjusting for age, sex, race, highest education, income, marital status and health insurance, having a discussion about screening and receiving a specific test recommendation were associated with being up to date with CRC screening (Table). Conclusion: Uptake of CRC screening is better when providers discuss CRC screening and make specific CRC screening test recommendations. Table: Association of the patterns of CRC screening recommendations with being up to date with CRC screening

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3565. doi:1538-7445.AM2012-3565
Abstract 357: Nonclinical tumor efficacy studies of [18F]AH113804, a novel PET imaging agent with high affinity for the human c-Met receptor
Authors: Evans Paul M. , Battle Mark , Getvoldsen Gareth , McRobbie Graeme , Bjerke Roger , Morrison Matthew , Johannesen Edvin , Dalsgaard Grethe T. 
Published: August 2012

Abstract
c-Met, the tyrosine-kinase receptor for hepatocyte growth factor (HGF)/scatter factor, is involved in tumour growth, invasion and metastasis in many human cancers of epithelial origin. Various tumour types are reported to overexpress c-Met, whilst expression in most normal tissues is relatively low. [18F]AH113804 is a peptide-based molecular imaging agent being developed by GE Healthcare for the in vivo evaluation of tumour and metastatic c-Met expression by PET imaging. In vitro affinity studies with fluorescently labelled analogues confirmed that whilst the AH113804 peptide had high affinity for human c-Met (hc-Met), there was limited or no affinity for dog or rodent c-Met, respectively. In mice, relatively high uptake of [18F]AH113804 was observed in human xenograft tumours known to express high levels of hc-Met, with rapid clearance from key background tissues such as muscle (tumour to muscle ratio of &gt;5 achieved by 30 minutes post-injection). This biodistribution profile allowed the tumour to be clearly visualised by micro-PET imaging. Tumour uptake was significantly reduced by co-administration of excess non-radioactive peptide, confirming tumour uptake was specific. Tumour uptake of [18F]AH113804 was also shown to correlate with expression of hcMet, with a relative retention of 2.0±0.1, 1.2±0.2 and 0.7±0.2% retained dose per gram normalised for body weight (% rd/g/100g bw) 60 minutes post-injection in xenograft tumours with relatively high (HT-29 tumours), lower (U87 tumours) and no (LLC tumours) expression of hc-Met respectively (as assayed by ELISA). Finally, 111InCl3 was used in a dual tumour model as a non-specific marker of blood pool to confirm differences in tumour uptake were not related to differences in tumour blood pool or delivery. There was a significant difference in [18F]AH113804 uptake between HT-29 (2.2±0.8% rd/g/100 g bw) and LLC (0.9±0.2% rd/g/100 g bw) tumours (p&lt;0.001) 30 minutes post-injection, whilst uptake of 111InCl3 was similar for the two tumour types (HT-29; 0.9±0.2% rd/g/100 g bw, LLC; 1.1±0.2% rd/g/100 g bw). Overall, these results confirmed that [18F]AH113804 has desirable properties for a c-Met targeted molecular imaging agent. Since there are a number of anti-c-Met therapies in clinical development, [18F]AH113804 has potential to be used as an aid in therapy selection and/or monitoring. Furthermore, [18F]AH113804 may be of use in patient stratification and prediction of patient outcome for specific cancers.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 357. doi:1538-7445.AM2012-357
Abstract 3571: UKLS - United Kingdom Lung Cancer Screening Trial
Authors: Field John K. , Baldwin David , Stephen Duffy W. , Devaraj Anand , Hansell David M. 
Published: August 2012

Abstract
In the UK 33,500 individuals die from lung cancer each year. The effectiveness of screening pre-symptomatic individuals urgently requires evaluation. The aim of UK Lung cancer Screening trial (UKLS) is to provide data required for an informed decision about the desirability of introducing population screening for lung cancer in the UK. The aim of the UKLS is to demonstrate a 25-30% mortality advantage and cost effectiveness of the screening. The UKLS pilot has started to recruit in 2011. The pilot sites are based at the Liverpool Heath & Chest Hospital, Liverpool and the Papworth Hospital, Cambridgeshire with a second reading site at the Royal Brompton Hospital, London. It will randomise 4,000 high risk patients identified by the Liverpool Lung Project (LLP) Risk Prediction Model. If the pilot trial is successful and funding is available, we plan to randomise a further 28,000 subjects from seven centres in the UK. Individuals are invited to participate if they have at least 5% risk of developing lung cancer over 5 years as predicted by the LLP risk model. The “Wald Single Screen” Design has been chosen for the UKLS pilot trial. Individuals meeting the inclusion/exclusion criteria will be sent invitations to participate and selected on the basis of the LLP risk questionnaire and selected to attend one of the pilot recruitment sites. After consent has been obtained, the participant will undertake spirometry and be asked to provide specimens (of blood, oral and nasal brushings and sputum) and to complete baseline lifestyle, psychosocial, and health economic questionnaire. Participants will be randomised to the study arm and will have a single low dose computed tomography scan (CT); those in the control arm will have usual care (no CT). CT scans will be read both locally and centrally and volumetric analysis will be performed on detected nodules. Both arms will be followed up for lung cancer incidence and mortality. Mortality will be documented after 10 years of follow-up. Modelling has resulted in the development of the UKLS care pathway to manage identified nodules. The aim of the main UKLS trial is to assess whether screening by low dose CT will confer a mortality advantage of 30% and also be cost effective for the UK population.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3571. doi:1538-7445.AM2012-3571
Abstract 3574: Detection of serum CYFRA 21-1 as a biomarker for stratification of ovarian cancer risk in women with a pelvic mass
Authors: Li Zhong-Qian , Smalley Robert J. , Glover Curtis L. , Radwan Rachel R. , Raju Savitha , Falcone Katherine L. , Fegely Maryellen , He Kuanglin , Kettlety Timothy R. 
Published: August 2012

Abstract
CYFRA 21-1 is a known lung cancer biomarker. In subjects with ovarian cancer (N = 159) and those with benign gynecological diseases (N = 53), serum CYFRA 21-1 reported a sensitivity (SN) of 44% and a specificity (SP) of 95% for ovarian cancer detection at a cut-off value of 2.4 ng/mL using an ELISA assay (Hasholzner U, et al, 1994). Another report showed a SN of 41% and a SP of 95% for ovarian cancer (N = 37) versus benign ovarian cysts, endometriosis, pelvic inflammatory disease, bowel disease and liver cirrhosis (N = 168) using an ELISA assay (Tempfer C, et al, 1998). We carried out a pilot study to evaluate the serum CYFRA 21-1 as a biomarker for stratification of ovarian cancer risk in women with a pelvic mass. Methods: ARCHITECT CYFRA 21-1 was used to measure the levels of serum CYFRA 21-1. Single point frozen serum samples from 171 female subjects with a pelvic mass were randomly selected from the archive clinical trial described by Moore R et al (2009). Of the 171 subjects, 42 had epithelial ovarian cancer (EOC), 5 with low malignant potential tumor (LMP) and 124 with benign pelvic masses. Results: To stratify EOC from benign pelvic masses and LMP, the following performance was obtained for serum CYFRA 21-1: Notes: The cutpoints were set at 1.2 and 1.8 ng/mL to reach a 75% and 95% SP, respectively. Conclusion: Serum CYFRA 21-1 appears to be a useful biomarker for stratification of EOC from benign pelvic mass and LMP.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3574. doi:1538-7445.AM2012-3574
Abstract 3580: Pre-diagnostic alcohol consumption and breast cancer recurrence and survival in postmenopausal women
Authors: Chang-Claude Jenny C. 
Published: August 2012

Abstract
Introduction: Alcohol consumption has been consistently associated with breast cancer risk. However, studies on its association with breast cancer survival produced inconsistent results. Methods: We assessed the association of alcohol consumption (in four categories &lt;0.5 g/d, 0.5 to &lt;6.0 g/d, 6.0 to &lt;12.0 g/d, α12.0 g/d, and continuous) with survival and recurrence in a prospective cohort study in Germany of 2,706 postmenopausal breast cancer patients aged 50-74 years after excluding those with previous cancer and/or missing information on alcohol intake. Patients were diagnosed between 2001 and 2005 and vital status, causes of death, and recurrences were verified through the end of 2009. Delayed-entry Cox proportional hazards models were stratified by age at diagnosis and study centre and adjusted for other prognostic factors. Fractional polynomials were used to assess the true dose-response relation for alcohol consumption. Results: Women were enrolled in the study a median time of 105 days after diagnosis. Median follow-up times from recruitment until death/censoring or recurrence/censoring were 5.5 years and 5.6 years, respectively. Overall, 326 deaths occurred, 239 (73.3%) due to breast cancer. Further causes of death were other cancers (n=41, 12.6%), cardiovascular disease (n=22, 6.7%), and other causes (n=24, 7.4%). Of the 2,199 patients with stage I to IIIa disease and available data on recurrence status, 250 had a breast cancer recurrence. Alcohol consumption ≤ 12 g/day compared to &lt; 0.5 g/day was linearly associated with a statistically significantly higher breast cancer mortality (HR, 1.71; 95% CI, 1.12 to 2.62; P for trend = 0.03). Results were no longer statistically significant when restricted to Stage I-IIIa patients (HR, 1.28; 95% CI, 0.75 to 2.20). There was no effect modification by body mass index, hormone replacement therapy use, and estrogen receptor status. Alcohol consumption ≤ 12 g/day was not associated with overall mortality (HR, 1.27; 95% CI, 0.90 to 1.80) and mortality due to other causes (HR, 0.73; 95% CI, 0.38 to 1.42). Also, no association with breast cancer recurrence was found (HR, 1.05; 95% CI, 0.71 to 1.56). Conclusion: Consumption of more than 12 g alcohol (equivalent to one alcoholic drink) per day is associated with increased breast cancer mortality but not with breast cancer recurrence.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3580. doi:1538-7445.AM2012-3580
Abstract 3587: Effect of race on outcome in women with uterine cancers
Authors: Nevadunsky Nicole S. , Smotkin David , Einstein Mark , Harris Kimala , Kim Ryung , Goldberg Gary 
Published: August 2012

Abstract
Background: Incidence rates for malignant tumors of the uterine corpus have been reported to be lower among women of color than among whites, whereas mortality rates have been reported to be higher among African-American women and women of Latina origin. Reasons for the higher level of mortality among women of color are currently unknown. Methods: After Institutional Review Board approval, we accessed the prospective clinical databases in the Division of Gynecologic Oncology at our institution. We abstracted socio-demographic and survival data from all women who were diagnosed with endometrial cancer from January 1990-January 2010. Pathology records were reviewed and the final pathology confirmed. Results: Nine hundred and ninety patients were identified. Racial distribution was 381 (38%) white, 310 (31%) black, 231 (23%) Hispanic, 21 (2%) other, and 72 (3%) unknown or unclassified. Five hundred and ninety-six (60%) patients had Type I endometriod histological subtype. At time of censor, 269 (27%) were confirmed deceased. The hazard ratio for black verses white women was 1.91 (p&lt;0.001) when all histological subtypes were included. However, when patients were divided into Type I and Type II histological subtypes there was no significant difference in survival by race. Conclusion: Our data show no difference in survival among women of Asian, African-American/Caribbean, and Caucasian races with uterine cancer after control for histological subtype.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3587. doi:1538-7445.AM2012-3587